Forte Biosciences FY2024 net loss $35.5M; FB102 celiac trial topline expected Q2 2025

Forte Biosciences, Inc.

2025-Q1 EPS reported -$1.37

FY2024 net loss $35.5M ($12.17 diluted EPS); operating expenses $36.6M vs $32.5M in 2023.
Cash and investments $58.4M at 12/31/2024; raised $53M in Nov 2024 private placement.
FB102 celiac trial on track: nearly half completed, no dropouts, topline data expected Q2 2025.
First FB102 vitiligo patient dosing expected shortly.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.